Skip to main content
Top
Published in: Breast Cancer 4/2017

01-07-2017 | Original Article

Overcalling low-risk findings: grouped amorphous calcifications found at screening mammography associated with minimal cancer risk

Authors: Madoka Iwase, Hiroko Tsunoda, Kanako Nakayama, Emiko Morishita, Naoki Hayashi, Koyu Suzuki, Hideko Yamauchi

Published in: Breast Cancer | Issue 4/2017

Login to get access

Abstract

Background

Because of the increasing availability of screening mammography and spread of information about its benefits, the incidence of early breast cancer has been increasing in Japan. However, screening mammography can result in overdiagnoses or false positives, causing in some subjects undergoing unnecessary invasive procedures. The current mammography guidelines recommend further investigation of subjects with grouped amorphous calcifications; this recommendation may have resulted in overdiagnoses or false positives.

Methods

We retrospectively reviewed the charts of patients who had undergone screening mammography in the screening unit of our institution from January 2011 to December 2012 and been found to have grouped amorphous calcifications. Of the 233 such cases, 17 had been lost to follow-up, whereas whether the lesions were actually benign or malignant had been determined in the remaining 216 (92.7%).

Results

Six (2.8%) of 216 subjects with grouped amorphous calcifications were diagnosed as having malignancy and the remaining 210 (97.2%) as having benign lesions. Four of the six cases (1.9%) with malignancy had ductal carcinoma in situ and two (0.9%) 3 and 4 mm diameter invasive cancers of luminal type and nuclear grade 1.

Conclusions

Grouped amorphous calcifications identified on screening mammography contribute minimally to detection of breast cancer and are not thought to be associated with any identifiable improvement in prognosis; present recommendations concerning this finding may result in false positives and overdiagnoses.
Literature
1.
go back to reference The Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.CrossRef The Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.CrossRef
2.
go back to reference Siu A, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:279–96.CrossRefPubMed Siu A, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:279–96.CrossRefPubMed
3.
go back to reference Japan Radiological Society/Japanese Society of Radiological Technology Edis. Mammography guideline [in Japanese]. Tokyo: Igaku Shoin; 2014. Japan Radiological Society/Japanese Society of Radiological Technology Edis. Mammography guideline [in Japanese]. Tokyo: Igaku Shoin; 2014.
4.
go back to reference Ohuchi N, editor. Japanese guidelines for quality assurance in mammography screening researchers on quality and efficacy improvement of breast cancer screening, Glant-in-aid for Cancer Research supported by the Ministry of Health, Labour and Welfare, Japan. 2005. Ohuchi N, editor. Japanese guidelines for quality assurance in mammography screening researchers on quality and efficacy improvement of breast cancer screening, Glant-in-aid for Cancer Research supported by the Ministry of Health, Labour and Welfare, Japan. 2005.
5.
go back to reference Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.CrossRefPubMed Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.CrossRefPubMed
7.
go back to reference Morimoto T, Kasahara Y, Tsunoda H, Tangoku A. Measures for reducing over-diagnosis in breast cancer screening [in Japanese]. J Jpn Assoc Breast Cancer Screen. 2014;23:337.CrossRef Morimoto T, Kasahara Y, Tsunoda H, Tangoku A. Measures for reducing over-diagnosis in breast cancer screening [in Japanese]. J Jpn Assoc Breast Cancer Screen. 2014;23:337.CrossRef
8.
go back to reference Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Rydén S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341:973–8.CrossRefPubMed Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Rydén S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341:973–8.CrossRefPubMed
9.
go back to reference Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909–19.CrossRefPubMed Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909–19.CrossRefPubMed
10.
go back to reference Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J. 1992;147:1459–76. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J. 1992;147:1459–76.
11.
go back to reference Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J. 1992;1477:1488. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J. 1992;1477:1488.
12.
go back to reference Miller ABB, Wall C, Baines CJJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. Miller ABB, Wall C, Baines CJJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
13.
go back to reference Ryu EB, Chang JM, Seo M, Kim SA, Lim JH, Moon WK. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound. Eur Radiol. 2014;24:2227–35.CrossRefPubMed Ryu EB, Chang JM, Seo M, Kim SA, Lim JH, Moon WK. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound. Eur Radiol. 2014;24:2227–35.CrossRefPubMed
14.
go back to reference Terminology and Diagnostic Criteria Committee Japan Society of Ultrasonics in Medicine. Recall criteria for ultrasound breast cancer screening. J Med Ultrason. 2016;43:301–13. Terminology and Diagnostic Criteria Committee Japan Society of Ultrasonics in Medicine. Recall criteria for ultrasound breast cancer screening. J Med Ultrason. 2016;43:301–13.
Metadata
Title
Overcalling low-risk findings: grouped amorphous calcifications found at screening mammography associated with minimal cancer risk
Authors
Madoka Iwase
Hiroko Tsunoda
Kanako Nakayama
Emiko Morishita
Naoki Hayashi
Koyu Suzuki
Hideko Yamauchi
Publication date
01-07-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0742-z

Other articles of this Issue 4/2017

Breast Cancer 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine